Powder: -20°C for 3 years | In solvent: -80°C for 1 year
B2 (Linazolamide intermediate B impurity 2) promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 16,000 | |||
5 mg | 在庫あり | ¥ 35,500 | |||
10 mg | 在庫あり | ¥ 57,000 | |||
25 mg | 在庫あり | ¥ 96,000 | |||
50 mg | 在庫あり | ¥ 137,000 | |||
100 mg | 在庫あり | ¥ 198,000 | |||
500 mg | お問い合わせ | ¥ 395,000 |
説明 | B2 (Linazolamide intermediate B impurity 2) promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease |
別名 | Linazolamide intermediate B impurity 2, CPNQ, 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline |
分子量 | 396.83 |
分子式 | C20H17ClN4O3 |
CAS No. | 115687-05-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 2 mg/mL
DMSO: 50 mg/mL (126 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
B2 115687-05-3 Chromatin/Epigenetic DNA Damage/DNA Repair Others Sirtuin Parkinson’s diseases Huntington’s diseases Linazolamide intermediate B impurity 2 B 2 Inhibitor CPNQ B-2 inhibit 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline inhibitor